BRAF and melanoma: While others have identified signatures from transcriptomic or proteomic data that correlate to sensitivity, to attempt to expand vemurafenib use beyond BRAF-V600E mutations [25], the clinical reality is that the FDA-approved application of vemurafenib requires the detection of a BRAF-V600E mutation in advanced stage melanoma [5].